Summary of randomized PhaseⅡandⅢclinicaltrials evaluating bevacizumabinfirst-line therapy of advanced malignant pleural mesothelioma MPM免疫治疗临床试验:CM743首个且唯一Ⅲ期阳性结果的临床研究 2L+单药 2L+联合 一线联合 新辅助 16年来首个获批MPM...
Nivolumab plus ipilimumab has shown clinical benefit in other tumour types, including first-line non-small-cell lung cancer. We hypothesised that this regimen would improve overall survival in MPM. Methods This open-label, randomised, phase 3 study (CheckMate 743) was run at 103 hospitals across...
然而,最近的联合试验,包括CheckMate 9LA[10]和针对间皮瘤的CheckMate 743[19],采用了固定剂量的纳武利尤单抗,每2周240 mg,或者每3周360 mg。药代动力学数据表明,与基于体重的给药剂量相比,固定剂量的ICIs产生的药物暴露与之相似[15...
Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 2021;397:375-86. [Crossref] [PubMed] Goldstein DA, Gordon N, Davidescu M, et al. A...
In CheckMate 743 (NCT02899299), a phase III randomized trial, NIVO+IPI provided statistically significant and clinically meaningful improvement in overall survival vs standard-of-care chemo in patients (pts) with unresectable MPM. Here, we present PRO results. Methods Pts ≥18 y with MPM were ra...
结果:研究共招募分析743 例患者(纳武利尤单抗,n = 371;索拉非尼,n = 372)。结果显示,接受纳武单抗和索拉非尼治疗患者的平均OS分别为16.4个月和14.7个月(HR = 0.85;95% CI:0.72-1.02;p = 0.075),平均PFS分别为3.8个月和3.9个月(HR = 0.98;95% CI:0.82-1.18)。
结果:研究共招募分析743 例患者(纳武利尤单抗,n = 371;索拉非尼,n = 372)。结果显示,接受纳武单抗和索拉非尼治疗患者的平均OS分别为16.4个月和14.7个月(HR = 0.85;95% CI:0.72-1.02;p = 0.075),平均PFS分别为3.8个月和3.9个月(HR = 0.98;95% CI:0.82-1.18)。
Checkmate 743–previously untreated unresectable malignant pleural mesothelioma, in combination with YERVOY; Checkmate 214–previously untreated renal cell carcinoma, in combination with YERVOY; Checkmate 9ER–previously untreated renal cell carcinoma, in combination with cabozantinib; Checkmat...
Checkmate 743–previously untreated unresectable malignant pleural mesothelioma, in combination with YERVOY; Checkmate 214–previously untreated renal cell carcinoma, in combination with YERVOY; Checkmate 9ER–previ...
结果:研究共招募分析743 例患者(纳武利尤单抗,n = 371;索拉非尼,n = 372)。结果显示,接受纳武单抗和索拉非尼治疗患者的平均OS分别为16.4个月和14.7个月(HR = 0.85;95% CI:0.72-1.02;p = 0.075),平均PFS分别为3.8个月和3.9个月(...